Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1165]

Paediatric ALL with brain metastases

Dr Christina Halsey - University of Glasgow, Glasgow, UK

Paediatric ALL with brain metastases ( Dr Christina Halsey - University of Glasgow, Glasgow, UK )

miRNA screening for germ cell tumours

Dr Matthew Murray - University of Cambridge, Cambridge, UK

miRNA screening for germ cell tumours ( Dr Matthew Murray - University of Cambridge, Cambridge, UK )

ALK mutations in paediatric tumours

Dr Suzanne Turner - Cambridge University, Cambridge, UK

ALK mutations in paediatric tumours ( Dr Suzanne Turner - Cambridge University, Cambridge, UK )

Standards in quality for genomic tests

Dr Christine Vietz - Foundation Medicine, Cambridge, USA

Standards in quality for genomic tests ( Dr Christine Vietz - Foundation Medicine, Cambridge, USA )

NCI’s precision medicine initiatives

Dr Shakun Malik - National Cancer Institute, USA

NCI’s precision medicine initiatives ( Dr Shakun Malik - National Cancer Institute, USA )

Screening, surgical cure and new developments: Q & A

Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco

Screening, surgical cure and new developments: Q & A ( Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco )

Screening, surgical cure and new developments: How to organise a national...

Prof John Field - University of Liverpool, Liverpool, UK

Screening, surgical cure and new developments: How to organise a national screening programme ( Prof John Field - University of Liverpool, Liverpool, UK )

Screening, surgical cure and new developments: How to avoid false positives in...

Dr Claudia Henschke - Mount Sinai Hospital, New York, USA

Screening, surgical cure and new developments: How to avoid false positives in lung cancer screening ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )

Omics, early detection and novel therapies: Q & A

Dr Murrell and Dr Pardo

Omics, early detection and novel therapies: Q & A ( Dr Murrell and Dr Pardo )

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )

More from ecancer